- Sourcews Report
- File
- HTML
- Size
- 24 Ko
- URL response
- 100%
- Source quality
- 94%
- Sourcews Explorer
Fresenius Kabi strengthens its position in i.v. drugs by acquiring Dabur Pharma, a leading manufacturer of oncology generics
20.04.08 - 15:29 ... source : Fresenius
... 20.04.2008 Bad Homburg v.d.H. Fresenius Kabi, a business segment of health care group Fresenius, continues its growth strategy in intravenously administered drugs (i.v. drugs). The company today announced the acquisition of 73.3 % of the share capital of the Indian company Dabur Pharma Ltd. for a price of INR 8,782 million (€ 139 million) or INR 76.50 per share in cash. In accordance with Indian regulations, Fresenius Kabi also announced a public offer to acquire up to a further 20 % shareholding for a price of INR 76.50 per share in cash. Fresenius Kabi has entered into an agreement with a third party to secure the participation of 2.4 % of Dabur Pharma's share capital in the public offer. Dabur Pharma, headquartered in New Delhi, is one of the leading suppliers of generic drugs and active pharmaceutical ingredients (API) to treat cancer. The co ...» Next (HTML)
Similar news
93% | 07.04.08 - 23:50 ... source : Astral Media - Canada
... Movie Network announced the rollout of the final two components of an extensive three-phase rebrand initiative to support its "Always Riveting" brand position. The Network has unveiled a new on-air, off-air and online look to support the "Always Riveting" tagline ...
93% | 02.04.08 - 12:43 ... source : Siemens
... Electronics Ltd, the second-largest fire safety company in Korea. With this acquisition Building Technologies (BT), a Division of Siemens Industry Sector, expands its position as global leader in the fire safety market. In addition BT reinforces its position in the ...
92% | 22.02.08 - 12:41 ... source : Komerční Banka
... banka published today its unaudited consolidated financial results under IFRS (International Financial Reporting Standards) for the year 2007. Compared to 2006, the net profit of KB Group increased by 21.9% to CZK 11,225 million. Komerční banka Group's results were not ...
90% | 07.04.08 - 15:14 ... source : Fresenius
... KGaA ("The Company") today announced that the United States District Court for the Northern District of California issued orders in the long standing patent case initiated by the Company to establish the invalidity of certain patents claims alleged to apply ...
89% | 02.04.08 - 13:37 ... source : Fresenius
... KGaA ("the Company"), the world's largest provider of Dialysis Products and Services, today reports that Standard & Poor's has assigned upgraded debt and recovery ratings to the Company's unsecured debt issues. Based on a recovery analysis the rating of Trust ...
